Free Trial

Curis (CRIS) Competitors

Curis logo
$1.84 +0.09 (+5.14%)
Closing price 01:59 PM Eastern
Extended Trading
$1.78 -0.06 (-2.99%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRIS vs. DOMH, ACHV, FBIO, SABS, BOLT, MTEM, AMGN, GILD, VRTX, and REGN

Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Dominari (DOMH), Achieve Life Sciences (ACHV), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry.

Curis vs. Its Competitors

Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Dominari has a net margin of -167.73% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Dominari's return on equity.

Company Net Margins Return on Equity Return on Assets
Curis-376.08% N/A -97.14%
Dominari -167.73%-91.67%-77.80%

In the previous week, Curis had 1 more articles in the media than Dominari. MarketBeat recorded 1 mentions for Curis and 0 mentions for Dominari. Curis' average media sentiment score of 0.00 equaled Dominari'saverage media sentiment score.

Company Overall Sentiment
Curis Neutral
Dominari Neutral

30.0% of Curis shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 5.5% of Curis shares are held by insiders. Comparatively, 33.0% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Curis presently has a consensus price target of $17.00, suggesting a potential upside of 823.91%. Given Curis' stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than Dominari.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dominari
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Curis has a beta of 3.6, suggesting that its share price is 260% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Dominari has higher revenue and earnings than Curis. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curis$10.91M1.76-$43.39M-$6.23-0.30
Dominari$18.15M4.25-$14.70M-$4.50-1.17

Summary

Dominari beats Curis on 8 of the 15 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRIS vs. The Competition

MetricCurisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.25M$2.89B$5.49B$9.01B
Dividend YieldN/A2.64%5.39%4.09%
P/E Ratio-0.3021.5627.4320.06
Price / Sales1.76281.29398.25108.31
Price / CashN/A41.4736.1356.90
Price / Book-2.597.518.085.67
Net Income-$43.39M-$55.05M$3.16B$248.47M
7 Day Performance-17.12%3.16%2.12%2.90%
1 Month Performance-20.00%5.92%4.43%5.75%
1 Year Performance-70.56%5.82%35.62%21.36%

Curis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRIS
Curis
2.383 of 5 stars
$1.84
+5.1%
$17.00
+823.9%
-72.0%$19.25M$10.91M-0.3060News Coverage
DOMH
Dominari
0.3594 of 5 stars
$5.44
-2.0%
N/A+163.8%$81.27M$18.15M0.004Gap Up
ACHV
Achieve Life Sciences
1.6251 of 5 stars
$2.26
+1.3%
$14.33
+534.2%
-50.8%$77.35MN/A-1.6920Gap Up
High Trading Volume
FBIO
Fortress Biotech
2.1685 of 5 stars
$1.86
+2.2%
$21.00
+1,029.0%
+9.6%$53.82M$57.67M-0.83170Gap Up
SABS
SAB Biotherapeutics
3.6079 of 5 stars
$1.76
+3.8%
$13.25
+655.0%
-38.8%$15.70M$1.32M0.00140Positive News
Gap Up
BOLT
Bolt Biotherapeutics
3.0184 of 5 stars
$5.77
+2.9%
$50.00
+766.6%
-59.8%$10.75M$7.69M-0.1790News Coverage
Positive News
High Trading Volume
MTEM
Molecular Templates
N/AN/AN/AN/A$1K$23.48M0.00260
AMGN
Amgen
4.4545 of 5 stars
$279.21
+0.8%
$307.82
+10.2%
-4.5%$149.01B$33.42B25.4828,000Positive News
GILD
Gilead Sciences
4.8439 of 5 stars
$110.87
+0.2%
$110.55
-0.3%
+63.0%$137.67B$28.75B23.3417,600Positive News
Insider Trade
VRTX
Vertex Pharmaceuticals
4.6765 of 5 stars
$445.20
+0.9%
$511.62
+14.9%
-3.5%$113.32B$11.02B-113.576,100Positive News
REGN
Regeneron Pharmaceuticals
4.9519 of 5 stars
$525.00
+0.8%
$813.57
+55.0%
-47.6%$56.25B$14.20B13.3715,106Trending News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:CRIS) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners